These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36071083)

  • 1. Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic.
    Heidler F; Baldt J; Frahm N; Langhorst SE; Mashhadiakbar P; Streckenbach B; Burian K; Zettl UK; Richter J
    Sci Rep; 2022 Sep; 12(1):15147. PubMed ID: 36071083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination Setting of Patients with Autoimmune Diseases in Times of Severe Acute Respiratory Syndrome Coronavirus Type 2 Pandemic Using the Example of Multiple Sclerosis Patients: A Longitudinal Multicenter Study.
    Heidler F; Baldt J; Frahm N; Langhorst SE; Mashhadiakbar P; Streckenbach B; Zettl UK; Richter J
    Eur Neurol; 2022; 85(2):104-111. PubMed ID: 34743082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States.
    Ehde DM; Roberts MK; Herring TE; Alschuler KN
    Mult Scler Relat Disord; 2021 Apr; 49():102788. PubMed ID: 33508570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in willingness to COVID-19 vaccination in China: Two online surveys during the pandemic.
    Huang N; Wang C; Han B; Zhao T; Liu B; Chen L; Xie M; Zheng H; Zhang S; Wang Y; Juan D; Liu Y; Lu Q; Cui F
    J Med Virol; 2022 Nov; 94(11):5271-5278. PubMed ID: 35848516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perceived Risk of SARS-CoV-2 at the Start of the COVID-19 Pandemic and Subsequent Vaccination Attitudes in Patients With Rheumatic Diseases: A Longitudinal Analysis.
    Duculan R; Mancuso CA
    J Clin Rheumatol; 2022 Jun; 28(4):190-195. PubMed ID: 35067512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran.
    Paybast S; Hejazi SA; Molavi P; Habibi MA; Naser Moghadasi A
    Mult Scler Relat Disord; 2022 Apr; 60():103712. PubMed ID: 35247752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine hesitancy among people with multiple sclerosis.
    Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
    Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies.
    Wallach AI; Schiebel M; Picone MA
    Mult Scler Relat Disord; 2022 Jul; 63():103856. PubMed ID: 35636275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Awareness of COVID-19 Symptoms, Risk Factors, and Vaccinations in Patients with Multiple Sclerosis.
    Krzystanek E; Jurczak A; Kocur K; Jurkiewicz J; Kaczmarczyk A
    Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35329050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey.
    Yurttas B; Poyraz BC; Sut N; Ozdede A; Oztas M; Uğurlu S; Tabak F; Hamuryudan V; Seyahi E
    Rheumatol Int; 2021 Jun; 41(6):1105-1114. PubMed ID: 33779780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations.
    Pugliatti M; Berger T; Hartung HP; Oreja-Guevara C; Bar-Or A
    Curr Opin Neurol; 2022 Jun; 35(3):319-327. PubMed ID: 35674075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis.
    Streckenbach B; Baldt J; Heidler F; Frahm N; Langhorst SE; Mashhadiakbar P; Burian K; Zettl UK; Richter J
    Vaccine; 2022 May; 40(23):3236-3243. PubMed ID: 35473660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
    Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
    CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
    Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
    Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 2: vaccine technologies].
    Monschein T; Zrzavy T; Löbermann M; Winkelmann A; Berger T; Rommer P; Hartung HP; Zettl UK
    Nervenarzt; 2021 Dec; 92(12):1283-1292. PubMed ID: 34232358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.
    Räuber S; Korsen M; Huntemann N; Rolfes L; Müntefering T; Dobelmann V; Hermann AM; Kölsche T; von Wnuck Lipinski K; Schroeter CB; Nelke C; Regner-Nelke L; Ingwersen J; Pawlitzki M; Teegen B; Barnett MH; Hartung HP; Aktas O; Albrecht P; Levkau B; Melzer N; Ruck T; Meuth SG; Kremer D
    J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):978-985. PubMed ID: 35193952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study.
    Wasserbauer M; Hlava S; Trojanek M; Stovicek J; Milota T; Drabek J; Koptová P; Cupkova A; Pichlerová D; Kucerova B; Coufal S; Keil R
    PLoS One; 2022; 17(9):e0273612. PubMed ID: 36054100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fear of COVID-19 predicts vaccination willingness 14 months later.
    Mertens G; Lodder P; Smeets T; Duijndam S
    J Anxiety Disord; 2022 May; 88():102574. PubMed ID: 35512598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
    Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
    Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.